TL;DR
- 1.Elite endurance athletes who train the hardest have lower resting MOTS-c than sedentary controls. The people who need it most are making the least of it.
- 2.BPC-157 protects the gut lining during high-volume training. Between 30 and 50 percent of Ironman athletes experience GI distress severe enough to affect race performance.
- 3.Every peptide in the triathlete stack, including BPC-157, TB-500, MOTS-c, and ipamorelin, is prohibited under the WADA 2026 Prohibited List. Default sanction: four years.
- 4.The 2026 FDA reclassification made several of these legally prescribable in the US. It changed nothing about WADA eligibility. A triathlete confirmed this in September 2025.
- 5.ACTN3 and ACE genotypes tell you whether your limiting factor is aerobic efficiency or tissue repair, and which layer of this stack to prioritize first.
In September 2025, a triathlete named Anthony McCauley accepted a four-year USADA suspension. The sanction listed BPC-157, TB-500, CJC-1295, and ipamorelin. Those four compounds appear in virtually every "peptide stack for endurance athletes" guide published this year. None of those guides mention the ban.
This article covers what each peptide actually does, what the most current research shows for endurance specifically, and the one finding that changes how you should think about MOTS-c. If you are subject to anti-doping testing, the WADA section is not optional reading.
Default WADA suspension for any peptide on the 2026 Prohibited List. The sanction applies in-competition and out-of-competition. A valid prescription does not change it.
What a peptide stack means in endurance training: A stack layers compounds that each address a separate bottleneck. BPC-157 protects the gut and manages systemic inflammation. TB-500 handles soft tissue microtrauma from cumulative load. MOTS-c addresses mitochondrial output. Ipamorelin amplifies the overnight growth hormone pulse that drives repair during sleep. None of these compete with each other. Done correctly, they cover four distinct weak points in a single training block.
What Peptides Are Endurance Athletes Actually Using?
The combination that shows up most often in triathlon and endurance cycling communities includes four compounds. Each has a distinct role in the training cycle. Before looking at the evidence, here is the function of each one.
BPC-157
Gut lining protection and systemic anti-inflammatory repair. Primary use: GI distress during high-volume training blocks and racing. Orally stable, targets the gut directly when swallowed.
TB-500
Systemic soft tissue repair and angiogenesis. Primary use: overuse injury prevention and connective tissue recovery between sessions. Addresses accumulated microtrauma in tendons and fascia.
MOTS-c
Mitochondrial efficiency and AMPK activation. Primary use: fat oxidation during sustained aerobic effort. Produced by your own mitochondria, with levels that change dramatically with training load.
Ipamorelin + CJC-1295
Growth hormone secretagogue pair. Primary use: amplifying the overnight GH pulse during deep sleep for structural repair. CJC-1295 extends the pulse from 90 minutes to roughly six hours.
See the Wolverine Stack 2026 update for the latest on how BPC-157 and TB-500 interact at the tissue level, including the 2024 prodrug finding that may change how you think about TB-500 dosing.
MOTS-c: Why the Athletes Who Train Hardest Have the Least of It
MOTS-c is encoded in your mitochondrial DNA, not your nuclear genome. Your mitochondria produce it as a signaling peptide during metabolic stress. It activates AMPK, shifts fuel utilization toward fat oxidation during exercise, and improves mitochondrial respiration. Acute exercise raises circulating MOTS-c. The story for chronic high-load training is completely different.
A 2024 study published in Nutrients by Alser et al. measured serum MOTS-c in 75 professional endurance athletes and compared them to 30 sedentary controls. The result: professional athletes had significantly lower resting MOTS-c than the sedentary group. Chronic high-volume endurance training appears to downregulate baseline MOTS-c production as an adaptive response. The athletes who train the hardest are making the least of it at rest.
"Endurance training enhances skeletal muscle mitochondrial respiration by promoting MOTS-c secretion during acute exercise. Resting serum MOTS-c is lower in high-volume trained athletes compared to sedentary controls, suggesting adaptive downregulation under chronic training load."
Feng et al., Free Radical Biology and Medicine, 2025
Number of professional endurance athletes in the Alser et al. (Nutrients 2024) study. All had lower resting MOTS-c than sedentary controls. Supplementation in this population is replacing what the body stopped making, not adding to what exercise already provides.
This reframes the entire MOTS-c decision. You are not adding a performance-enhancing substance on top of what hard training already produces. You are replacing the baseline that chronic load has reduced. For a 15-hour-per-week triathlete late in a base training block, that distinction is significant. For deeper context on the mechanism and what the decline looks like across decades, see the MOTS-c deep dive.
A third human study (Nutrients 2023, PMC10573682) found MOTS-c correlated with lower-body muscle strength but not peak VO2, which complicates the aerobic narrative. The AMPK activation and fat oxidation data from animal models is strong. Human performance data is still emerging. Treat MOTS-c as well-supported in mechanism, preliminary in human performance outcomes.
Why BPC-157 Matters for Race Day, Not Just Injury Recovery
Estimated percentage of Ironman and full-marathon athletes who experience GI distress significant enough to affect race performance or force slowing. GI failure is one of the most common reasons athletes do not finish, or finish far below predicted time.
Exercise-induced GI distress is not a fringe complaint. During prolonged aerobic effort, blood is redirected from the gut to working muscles. That ischemia damages the gut lining, increases intestinal permeability, and triggers nausea, cramping, and diarrhea in a large fraction of athletes who push hard enough for long enough. The longer the race, the worse the problem compounds.
BPC-157's key pharmacological property in this context is oral stability. It survives gastric acid and reaches the gut epithelium intact. In animal models from the laboratory of Predrag Sikiric, BPC-157 accelerated healing of GI lesions, protected the gut wall against NSAID and stress-induced damage, and reduced inflammatory cytokine output from intestinal tissue. A 2025 review in PMC (Sikiric et al., PMC11859134) covers the cytoprotective mechanism directly. No completed human RCTs exist for athletic GI use. The mechanism is plausible and the animal evidence is extensive.
Most athletes using BPC-157 report the most noticeable GI benefit during training blocks with four or more sessions per week. The common protocol is oral BPC-157 at 250 to 500 mcg daily, taken in the morning or pre-workout, for 6 to 8 weeks followed by a 4-week break. The BPC-157 and TB-500 half-life guide explains clearance windows and what that means for timing around hard sessions.
TB-500 and Ipamorelin: What the Evidence Actually Shows
TB-500 (Thymosin beta-4) promotes cell migration and angiogenesis. In animal models and a 2025 orthopaedics review (PMC12753158), it accelerated tendon, ligament, and skeletal muscle repair by driving myoblast migration and extracellular matrix remodeling. For endurance athletes, the relevant use case is overuse microtrauma: repetitive loading at high weekly volume creates microscopic damage in tendons and connective tissue faster than the body repairs it. TB-500 addresses the repair side of that imbalance. No human RCTs exist for athletic use.
Ipamorelin is a selective GH secretagogue. It triggers a GH pulse 30 to 60 minutes after injection without significantly raising cortisol or prolactin, which distinguishes it from older GHRPs. CJC-1295 without DAC extends the ipamorelin-triggered GH pulse from roughly 90 minutes to six hours, matching the natural GH release pattern during deep sleep. The foundational human pharmacokinetic data comes from Alba et al. in the Journal of Clinical Endocrinology and Metabolism (2006, PMID 16822960), showing sustained dose-dependent increases in GH and IGF-1 from CJC-1295 in healthy adults. No endurance-specific trials have been run.
The sleep dependency matters. Ipamorelin amplifies a pulse that only happens during slow-wave sleep. If your sleep architecture is disrupted by overtraining, travel, or altitude, the compound cannot do its job. Fix the sleep before adding the peptide. The peptide cycling guide covers how to structure on and off windows to prevent receptor blunting over a full training season.
Evidence tier for each compound in this stack
| Peptide | Highest evidence level | Human endurance data? | Primary use case |
|---|---|---|---|
| MOTS-c | Human observational (athletes vs. controls) | Yes, but no RCTs | Mitochondrial efficiency, fat oxidation |
| Ipamorelin / CJC-1295 | Human PK studies for GH secretion | GH data only, no performance outcomes | Overnight GH pulse, sleep-stage repair |
| BPC-157 | Animal RCTs (extensive) | No | Gut protection, anti-inflammatory |
| TB-500 | Animal models, case reports | No | Soft tissue and overuse injury repair |
Every Peptide in This Stack Is Banned by WADA. Here Is What That Actually Means.
The 2026 WADA Prohibited List classifies BPC-157 under S0 (Non-Approved Substances), TB-500 under S2 (Growth Factors and Mimetics), MOTS-c under S0, and ipamorelin and CJC-1295 under S2.2 (Growth Hormone Releasing Factors). The S0 category prohibits any substance not approved for human therapeutic use by a major regulatory authority, even if it is not explicitly named. Every peptide in this stack meets that threshold. None require a positive test to trigger a violation.
Strict liability means that if the substance is found in your sample, you are responsible, regardless of how it got there or who prescribed it. The default sanction for a first violation is four years. Aggravating circumstances, including social media promotion of banned substances to other athletes, can extend or complicate the sanction.
The September 2025 USADA sanction for triathlete Anthony McCauley (usada.org, published September 17, 2025) confirmed what many guides had not warned: a triathlete using BPC-157, TB-500, CJC-1295, and ipamorelin received a four-year suspension and lost all results from June 2024 onward. McCauley's case also included promotion of these compounds on social media to followers who competed under WADA rules. USADA treated that promotion as a separate violation.
The complicating factor for 2026 is the FDA reclassification. On April 22, 2026, HHS removed approximately 14 peptides from the Category 2 restricted compounding list, restoring the prescribing pathway at licensed compounding pharmacies. BPC-157, TB-500, ipamorelin, MOTS-c, and others are now legally obtainable with a physician's prescription in the US. That change has zero effect on WADA eligibility. A legal prescription in the US does not alter your status under the WADA Prohibited List. The USADA has published a dedicated explainer on BPC-157 specifically addressing this confusion.
What Your ACTN3, ACE, and EPOR Genes Say About This Stack
The peptides in this stack address different physiological bottlenecks. Which bottleneck is most limiting for you depends on your genotype. This is the angle that no existing endurance peptide guide covers, and it is the most useful for personalizing the stack before you spend anything.
ACTN3 R577X: The Muscle Fiber Gene
ACTN3 encodes alpha-actinin-3, a structural protein expressed exclusively in fast-twitch muscle fibers. The R577X variant creates a stop codon in XX homozygotes, eliminating alpha-actinin-3 expression. XX genotype individuals are over-represented among elite endurance athletes in multiple studies, because the absence of this protein shifts the muscle phenotype toward slow-twitch endurance characteristics. The tradeoff is lower peak power and, typically, less connective tissue microtrauma per training hour than power-dominant athletes. For XX carriers, MOTS-c and mitochondrial efficiency work is the higher-leverage layer of the stack. TB-500 matters less because the connective tissue stress is comparatively lower.
ACE I/D: The Engine Gene
The ACE insertion/deletion polymorphism determines angiotensin-converting enzyme activity. ACE I/I carriers have lower ACE activity, lower angiotensin II levels, and appear at higher rates in elite endurance events from marathon to rowing. ACE D/D carriers have higher ACE activity, tend toward power performance, and generate more cardiovascular and metabolic strain per unit of aerobic workload. D/D genotype athletes have higher inter-session recovery demands, which is why TB-500 and BPC-157 carry more weight in the stack for this profile than for I/I carriers with the same training volume.
EPOR: The Oxygen Delivery Gene
EPOR encodes the erythropoietin receptor. Rare gain-of-function EPOR variants produce supraphysiological responses to endogenous EPO, increasing red blood cell mass and oxygen delivery significantly above the normal range. This is the pathway the original Eero Mantyranta case made famous. More common functional EPOR variants create an oxygen delivery ceiling that training partially compensates. For athletes with lower-efficiency EPOR variants, the mitochondrial efficiency work addresses the metabolic side of oxygen utilization when the delivery side has a ceiling. MOTS-c and AMPK activation become more important relative to volume-based training increases.
Your 23andMe or AncestryDNA raw file contains ACTN3 rs1815739 and ACE rs4646994. Uploading it to your peptide genetics report calls both variants in under five minutes, along with COL5A1 and NOS3, which predict connective tissue injury risk and BPC-157 response respectively.
How to Structure This Stack Across a Training Season
Stacking all four compounds simultaneously across a full season is not the right approach. Each compound addresses a different phase of training stress. Layering them relative to your training calendar produces better results than running all of them continuously.
Base training: high mileage, low intensity
This is the phase for BPC-157 and TB-500. Cumulative soft tissue stress peaks during high-volume base blocks when intensity is low enough that you can push mileage. Daily oral BPC-157 at 250 to 500 mcg and twice-weekly TB-500 at 2 mg subcutaneous for 8 to 10 weeks builds the protective layer before intensity blocks accumulate additional inflammatory load.
Threshold and intensity blocks
Add ipamorelin (100 to 200 mcg subcutaneous before sleep) and MOTS-c (5 to 10 mg subcutaneous, three times per week) during intensity blocks. This is when overnight GH-driven repair and mitochondrial efficiency both matter most. The combined physiological demand on recovery systems peaks during threshold work, and these two compounds address that demand from two separate mechanisms.
Race taper and peak competition
Cycle off all compounds 4 to 6 weeks before a peak event. This allows natural hormone patterns to normalize and avoids any residual receptor blunting from continuous compound use during the taper window. For a full Ironman or A-race marathon, the taper itself is the recovery stimulus. Adding peptide load during the taper adds variables without meaningful benefit.
Verdict: The endurance athlete peptide stack has a coherent logic, each compound addressing a distinct training bottleneck, but the WADA risk is categorical for any athlete subject to anti-doping testing. No legal pathway around it exists.
For non-competing athletes and masters athletes not subject to testing, the stack is worth evaluating in the context of high-volume training blocks where gut distress, overuse injury, or poor recovery are the actual limiters. Your ACTN3 and ACE genotype tells you which layer to prioritize first. If you have existing 23andMe or AncestryDNA data, upload your raw file to see the full genetic breakdown for this stack. If you are starting from scratch, the DNA kit includes the complete endurance genetics panel.
Your DNA shapes how you respond to the peptides discussed above.
A personalized report scores 25+ peptides against your unique genetic profile — including the ones covered in this article.
Frequently asked questions
What peptides do endurance athletes use for performance and recovery?
The most commonly used combination is MOTS-c for mitochondrial efficiency and fat oxidation, BPC-157 for gut protection and systemic anti-inflammatory repair, TB-500 for soft tissue and overuse injury recovery, and ipamorelin or CJC-1295 for overnight growth hormone pulse amplification. Each compound targets a different bottleneck in the endurance training cycle. The evidence quality varies significantly, from human observational studies for MOTS-c to animal-only preclinical data for BPC-157 and TB-500.
Are peptides legal for triathletes and competitive endurance athletes?
No. Every peptide in the standard endurance stack, including BPC-157, TB-500, MOTS-c, ipamorelin, and CJC-1295, is prohibited under the WADA 2026 Prohibited List. In September 2025, a triathlete accepted a four-year suspension from USADA for using BPC-157, TB-500, CJC-1295, and ipamorelin. The 2026 FDA reclassification made several of these legally prescribable in the US but had zero effect on WADA eligibility. Having a physician's prescription does not protect an athlete from a doping sanction.
Does MOTS-c actually improve VO2 max in endurance athletes?
Animal models show MOTS-c activates AMPK, improves fat oxidation during aerobic effort, and enhances mitochondrial respiration in skeletal muscle during exercise. A 2023 human study found MOTS-c correlated with lower-body muscle strength but not peak VO2 max. No human randomized controlled trials measuring VO2 max outcomes from MOTS-c supplementation have been published as of mid-2026. Treat the aerobic performance claims as animal-model supported and human-data preliminary.
What is the best peptide for recovery after long training runs or rides?
BPC-157 and TB-500 address different recovery problems. BPC-157 is better suited to gut distress and systemic inflammation, which spike after very long efforts. TB-500 addresses connective tissue and soft tissue microtrauma, particularly tendons, fascia, and muscle damage from repetitive loading. Most high-mileage athletes benefit from both, with the priority determined by their primary limiting factor. Your COL5A1 and NOS3 genotype predict which one you respond to more strongly.
How does the ACTN3 gene affect which peptides matter most for endurance athletes?
ACTN3 R577X XX genotype individuals lack alpha-actinin-3 in fast-twitch fibers and are over-represented among elite endurance athletes. For XX carriers, the mitochondrial efficiency layer of the stack (MOTS-c) addresses the primary bottleneck more directly than connective tissue repair compounds. RR carriers are more power-dominant, generate higher connective tissue stress per training hour, and typically benefit more from prioritizing TB-500 and BPC-157 relative to MOTS-c.
Can you stack BPC-157 and ipamorelin together?
Yes. BPC-157 and ipamorelin target separate mechanisms and do not compete. BPC-157 addresses gut integrity and local tissue repair through eNOS and angiogenesis pathways. Ipamorelin stimulates GH release via the ghrelin receptor. The compounds have different administration routes, oral for BPC-157 and subcutaneous injection for ipamorelin, which also prevents any meaningful interaction. Most endurance protocols run BPC-157 continuously during training blocks and add ipamorelin during intensity phases when overnight GH-driven recovery is the priority.
This article is for informational and educational purposes only. It is not medical advice and does not diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before starting any peptide protocol. Individual results vary.